Replies to post #29054 on Ocata Therapeutics Inc fka OCAT

[rocky301]

rumit,

The transaction date equals issued shares so they have to use the close that day to "book" the value as you can see below. So yes, booked all shares around 9 cents. Taxes? Not sure, I know the BOD's and Caldwell shares will have taxes due after restriction is lifted. Lanza's were different as his shares released at 1MM per month. The 135MM shares that were issued didn't cost any of them a dime so taxes are taxes...like the lottery. Hopefully the "interim" won't do the same. Lanza's shares booked under R&D, BOD's and Caldwell under G&A..

"During the three months ended March 31, 2010, the Company issued a total of 21,726,102 shares of its common stock to its chief executive officer and chief scientific officer. Further, the Company is to issue an additional 97,746,696 shares of its common stock to the same officers. The Company recorded $10,752,552 in officer compensation expense for the value of these shares."
http://www.sec.gov/Archives/edgar/data/1140098/000101376210001063/form10q.htm

Research and Development Expenses
The increase in R&D expenditures during the three months ended March 31, 2010 as compared to the same period in 2009 is primarily due to 30,192,203 shares of common stock issued and to be issued to our chief scientific officer, valued at $2,717,298 during the three months ended March 31, 2010. Further, the Company hired new R&D employees, increased its R&D activity, and increased its patent legal costs during the three months ended March 31, 2010.

General and Administrative Expenses
General and administrative expenses for the three months ended March 31, 2010 and 2009 were $11,218,243 and $747,078, respectively, an increase of $10,471,165. This expense increase was primarily due to 89,280,595 shares of our common stock issued or to be issued to our chief executive officer, valued at $8,035,254, and another 16,773,597 shares of our common stock issued to our directors, valued at $1,533,513, during the three months ended March 31, 2010. Additionally, during the three months ended March 31, 2010, we experienced an increase in legal fees in our efforts to secure financing and in defending the Company in various legal matters.